ANDA 204095, held by PharmoBedient. Desvenlafaxine Succinate.
As of Nov 22, 2026, ANDA 204095 (Desvenlafaxine Succinate), held by PharmoBedient, was first approved by FDA on Jun 29, 2015, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2015 | Original application | Approved | None posted |
| Desvenlafaxine SuccinateEQ 50MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Discontinued |
| Desvenlafaxine SuccinateEQ 100MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Discontinued |
| Apr 9, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 23, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 23, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 31, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 31, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 31, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 31, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 29, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters